Literature DB >> 11313895

An hsRPB4/7-dependent yeast assay for trans-activation by the EWS oncogene.

H Zhou1, K A Lee.   

Abstract

Chromosomal fusions of the N-terminal region of the Ewings Sarcoma Oncogene (EWS-Activation-Domain, EAD) to the DNA-binding domains of a variety of cellular transcription factors, produce oncogenic proteins (EWS-fusion proteins (EFPs)) that cause a variety of malignancies. The EAD can act as a potent transcriptional activation domain and is required for the oncogenic activity of EFPs. Previous studies demonstrating a physical interaction between the EAD and the human RNA Polymerase II subunit hsRPB7 suggest a crucial role for RPB7 and its partner, RPB4, in EAD function. Homologues of hsRPB4/7 exist in S. cerevisiae, and here we describe an RPB4/7-dependent yeast assay for EAD-mediated trans-activation. Conditional yeast strains lacking RPB4 are defective for trans-activation by a Gal4/EAD fusion protein at the permissive temperature. Introduction of hsRPB4 alone is unable to rescue trans-activation, while a combination of hsRPB4 and hsRPB7 significantly rescues activity. These findings provide the first functional evidence for a direct role of the RPB4/7 complex in EAD-mediated trans-activation. In addition, the yeast assay provides a tractable system for further molecular analysis of EAD and RPB4/7 action.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313895     DOI: 10.1038/sj.onc.1204135

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Complete, 12-subunit RNA polymerase II at 4.1-A resolution: implications for the initiation of transcription.

Authors:  David A Bushnell; Roger D Kornberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-13       Impact factor: 11.205

2.  Loss of the Rpb4/Rpb7 subcomplex in a mutant form of the Rpb6 subunit shared by RNA polymerases I, II, and III.

Authors:  Qian Tan; Meredith H Prysak; Nancy A Woychik
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

3.  In vitro interaction between the N-terminus of the Ewing's sarcoma protein and the subunit of RNA polymerase II hsRPB7.

Authors:  Roumiana Todorova
Journal:  Mol Biol Rep       Date:  2008-07-08       Impact factor: 2.316

Review 4.  The TET family of proteins: functions and roles in disease.

Authors:  Adelene Y Tan; James L Manley
Journal:  J Mol Cell Biol       Date:  2009-09-24       Impact factor: 6.216

5.  A transcription assay for EWS oncoproteins in Xenopus oocytes.

Authors:  King Pan Ng; Felix Cheung; Kevin A W Lee
Journal:  Protein Cell       Date:  2010-11-09       Impact factor: 14.870

6.  The RNA Pol II sub-complex hsRpb4/7 is required for viability of multiple human cell lines.

Authors:  Yang Zhao; Kim K C Li; King Pan Ng; Chi Ho Ng; Kevin A W Lee
Journal:  Protein Cell       Date:  2012-10-17       Impact factor: 14.870

7.  Genomic location of the human RNA polymerase II general machinery: evidence for a role of TFIIF and Rpb7 at both early and late stages of transcription.

Authors:  Marilena Cojocaru; Célia Jeronimo; Diane Forget; Annie Bouchard; Dominique Bergeron; Pierre Côte; Guy G Poirier; Jack Greenblatt; Benoit Coulombe
Journal:  Biochem J       Date:  2008-01-01       Impact factor: 3.857

8.  Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins.

Authors:  King Pan Ng; Gary Potikyan; Rupert O V Savene; Christopher T Denny; Vladimir N Uversky; Kevin A W Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

9.  Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma.

Authors:  David Herrero-Martin; Argyro Fourtouna; Stephan Niedan; Lucia T Riedmann; Raphaela Schwentner; Dave N T Aryee
Journal:  Sarcoma       Date:  2011-11-10

10.  Crystal structure and RNA binding of the Rpb4/Rpb7 subunits of human RNA polymerase II.

Authors:  Hedije Meka; Finn Werner; Suzanne C Cordell; Silvia Onesti; Peter Brick
Journal:  Nucleic Acids Res       Date:  2005-11-10       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.